Avammune Therapeutics secures an undisclosed amount of funding from The Chennai Angels
- ByStartupStory | July 16, 2022
Avammune Therapeutics Inc. has received funding from The Chennai Angels for the completion of IND enabling studies for their immuno-oncology asset. Avammune is in advanced talks with significant pharma and biotech firms about partnering for the clinical translation of the assets, and concurrently with strategic investors about putting the assets through independent clinical testing.
Dr Aditya Kulkarni, Chief Scientific Officer, Avammune stated, “We are developing a revolutionary class of medications that harness the body’s first line of defence against infections to attack cancer. These extremely potent medications have the ability to overcome drug resistance. Due to their chemical origin, they can be administered by patients as oral tablets and may be more reasonably priced than biological medications.”
Sameer Mehta, Director of Mehta’s Multispecialty Hospital India Pvt Ltd and Lead Investor from The Chennai Angels said, “Millions of people are still affected by cancer each year despite significant advancements in the discovery and development of novel treatments. TCA is pleased to support Avammune in the creation of immuno-oncology assets.”
Arun B. Papaiah, CEO of Avammune said, “The company has been proven in numerous animal models and safety studies are about to begin. With the most recent funding, we hope to finish these partnerships and safety studies in time for clinical testing to begin next year, strengthening our diverse pipeline of cancer and autoimmune disease medications. Working as partners with The Chennai Angels is a delight.”
Also Read – Kerala-based Apparel brand G & A raises funding
About Avammune Therapeutics:
Avammune is an early-stage drug development company started in 2018 by Aditya Kulkarni and Arun B Papaiah has its sights set on Immuno-oncology, particularly the STING pathway. Avammune is concentrated on the creation of brand-new small-molecule STING pathway modulators to fight cancer and infectious disorders.
Follow Startup Story
Related Posts
